Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

FCRN inhibitor sales: Vyvgart dominates market

Vyvgart sees strong growth with CIDP approval

By Stephen Hansen, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
March 21, 2025 10:44 PM UTC

Argenx continues to build its dominant commercial position in the FCRN market thanks not only to its first-mover advantage but quick expansion into new indications.

For 2024, Argenx SE (Euronext:ARGX; NASDAQ:ARGX) reported $2.2 billion in sales of FCRN inhibitor Vyvgart efgartigimod, an increase of 84% vs. $1.2 billion in 2023...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Argenx S.E.

Johnson & Johnson

Ucb S.A.